4//SEC Filing
Chakraborty Tirtha 4
Accession 0001415889-25-003175
CIK 0001817229other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 9:22 PM ET
Size
46.9 KB
Accession
0001415889-25-003175
Insider Transaction Report
Form 4
Chakraborty Tirtha
CHIEF SCIENTIFIC OFFICER
Transactions
- Award
Common Stock
2025-02-03+52,500→ 221,272 total - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−24,410→ 0 totalExercise: $2.18Exp: 2030-03-09→ Common Stock (24,410 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−70,656→ 0 totalExercise: $1.90Exp: 2030-08-20→ Common Stock (70,656 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+70,656→ 70,656 totalExercise: $1.34Exp: 2030-08-20→ Common Stock (70,656 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−107,500→ 0 totalExercise: $2.41Exp: 2034-01-28→ Common Stock (107,500 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+107,500→ 107,500 totalExercise: $1.34Exp: 2034-01-28→ Common Stock (107,500 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+315,000→ 315,000 totalExercise: $1.34Exp: 2035-02-02→ Common Stock (315,000 underlying) - Tax Payment
Common Stock
2025-02-03$1.34/sh−1,163$1,558→ 168,772 total - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−28,800→ 0 totalExercise: $1.36Exp: 2029-09-24→ Common Stock (28,800 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+28,800→ 28,800 totalExercise: $1.34Exp: 2029-09-24→ Common Stock (28,800 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+24,410→ 24,410 totalExercise: $1.34Exp: 2030-03-09→ Common Stock (24,410 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−121,323→ 0 totalExercise: $6.53Exp: 2030-11-17→ Common Stock (121,323 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+121,323→ 121,323 totalExercise: $1.34Exp: 2030-11-17→ Common Stock (121,323 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−101,000→ 0 totalExercise: $8.63Exp: 2032-01-31→ Common Stock (101,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+101,000→ 101,000 totalExercise: $1.34Exp: 2032-01-31→ Common Stock (101,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−76,000→ 0 totalExercise: $5.31Exp: 2032-08-31→ Common Stock (76,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+76,000→ 76,000 totalExercise: $1.34Exp: 2032-08-31→ Common Stock (76,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-03+95,500→ 95,500 totalExercise: $1.34Exp: 2033-02-05→ Common Stock (95,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-03−95,500→ 0 totalExercise: $5.55Exp: 2033-02-05→ Common Stock (95,500 underlying)
Footnotes (11)
- [F1]Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").
- [F10]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.
- [F11]The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date.
- [F2]Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date.
- [F3]On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F4]Immediately exercisable.
- [F5]The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.
- [F6]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on December 16, 2020, in each case subject to the Reporting Person's continued service as of each such date.
- [F7]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.
- [F8]The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.
- [F9]The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.
Documents
Issuer
Vor Biopharma Inc.
CIK 0001817229
Entity typeother
Related Parties
1- filerCIK 0001840685
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 9:22 PM ET
- Size
- 46.9 KB